SK Biopharmaceuticals Co., Ltd.
326030
주식 순위
#4044
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
주가
$51.83
시가총액
$4.06B
변동 (1일)
0.60%
변동 (1년)
-30.72%
국가
KR
거래 SK Biopharmaceuticals Co., Ltd. (326030)
카테고리
Healthcare
SK Biopharmaceuticals Co., Ltd. (326030)의 P/S 비율
October 2026 기준 P/S 비율 TTM: 6.31
SK Biopharmaceuticals Co., Ltd.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 6.31입니다. 2024년 말 기준 P/S 비율은 15.89였습니다.
SK Biopharmaceuticals Co., Ltd.의 P/S 비율 기록 (2011 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 6.31 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 15.89 | -30.16% |
| 2023 | 22.75 | 0.17% |
| 2022 | 22.71 | 24.92% |
| 2021 | 18.18 | -96.10% |
| 2020 | 466.49 | 599.92% |
| 2019 | 66.65 | -99.07% |
| 2018 | 7.19K | 9,564.87% |
| 2017 | 74.43 | 5.37% |
| 2016 | 70.64 | -20.55% |
| 2015 | 88.91 | 2.53% |
| 2014 | 86.72 | 3.20% |
| 2013 | 84.03 | -14.35% |
| 2012 | 98.11 | -27.27% |
| 2011 | 134.89 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 10.02 | 58.83% |
US
|
|
| 40.55 | 542.65% |
US
|
|
| 3.96 | -37.22% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 60.80% |
NL
|
